Priya Rastogi, MD, on a Novel Approach to Predicting Benefit From Extended Letrozole Treatment for Breast Cancer

Posted: Wednesday, July 14, 2021

Priya Rastogi, MD, of the University of Pittsburgh, talks about how the 70-gene MammaPrint assay was used to identify subgroups of women with breast cancer for whom extended letrozole therapy is likely to be useful in extending disease-free survival, and the implications for clinical practice.